GlobalRPh Renal Dosing Masterv6.6
Evidence addition

Ubrogepant tablets (Ubrelvy)

Local official-label summaryBase record retrieved 2026-09-05See the evidence for this drug2 sources available - open source summaries, references and comparisons

Ubrelvy

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (2)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

Official source

Ubrogepant tablets (Ubrelvy) - selected U.S. label sections

Product / population
Adult UBRELVY oral treatment of an acute migraine; not preventive dosing.
Renal measure
Creatinine clearance in mL/min

Selected renal sections only, not a complete monograph. Exact product, indication, patient population, renal method and all other contraindications/interactions remain controlling.

Second independent renal reference and clinician adjudication remain pending; no all-indication, dialysis or pediatric dose may be inferred from an omitted field.

Severe renal impairment and ESRD

At CrCl 15-29 mL/min, use 50 mg for the initial dose. If needed, a second 50 mg dose may be given at least 2 hours later. Avoid use when CrCl is below 15.

Do not apply the unrestricted maximum

Use the renal-restricted initial and repeat doses, not a higher general-population dose. CYP3A and transporter interactions require separate review.

Source revision: Revision not captured; retrieval date is not the revision date. | Retrieved: 2026-09-05. Retrieval date is not the revision date.

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fd9f9458-fd96-4688-be3f-f77b3d1af6ab

Scope: Local label summary; independent clinical review pending. Not a two-source validated protocol. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Official product label

Ubrogepant tablets (Ubrelvy) - selected U.S. label sections

Adult UBRELVY oral treatment of an acute migraine; not preventive dosing.

Renal method: Creatinine clearance in mL/min
Retrieved: 2026-09-05

Read local renal resultOpen original reference
GlobalRPh RX List

GlobalRPh RX List - Ubrelvy

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Adults; oral UBRELVY; acute migraine. Selected renal and interaction constraints.

Renal method: CLcr in mL/min; renal table
Retrieved: 2026-09-07

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeUbrogepant tablets (Ubrelvy) - selected U.S. label sectionsGlobalRPh RX List - Ubrelvy
Choose two source checkboxes below.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fd9f9458-fd96-4688-be3f-f77b3d1af6ab

Product and population scope

Adult UBRELVY oral treatment of an acute migraine; not preventive dosing.

RDM32-ubrogepant-ubrelvy-scope · Source section: Editorial scope for the selected U.S. labelRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

Ubrogepant tablets (Ubrelvy) - selected U.S. label sections

Open original reference

Open / share this exact local source

U.S. product labeling / DailyMed · Adult UBRELVY oral treatment of an acute migraine; not preventive dosing.

Renal method: Creatinine clearance in mL/min
Source date: Revision not captured; retrieval date is not the revision date.
Retrieved: 2026-09-05

Local label summary; independent clinical review pending. Not a two-source validated protocol.

Severe renal impairment and ESRD

At CrCl 15-29 mL/min, use 50 mg for the initial dose. If needed, a second 50 mg dose may be given at least 2 hours later. Avoid use when CrCl is below 15.

RDM32-ubrogepant-ubrelvy-1 · Source locator: 2.2; 8.7

Do not apply the unrestricted maximum

Use the renal-restricted initial and repeat doses, not a higher general-population dose. CYP3A and transporter interactions require separate review.

RDM32-ubrogepant-ubrelvy-2 · Source locator: 2.2; 7

Source-specific limits

Selected renal sections only, not a complete monograph. Exact product, indication, patient population, renal method and all other contraindications/interactions remain controlling.

Second independent renal reference and clinician adjudication remain pending; no all-indication, dialysis or pediatric dose may be inferred from an omitted field.

Source identity and provenance
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fd9f9458-fd96-4688-be3f-f77b3d1af6ab
Retrieved
2026-09-05
DailyMed Set ID
fd9f9458-fd96-4688-be3f-f77b3d1af6ab
Renal-function method
Creatinine clearance in mL/min
Source date/version
Revision not captured; retrieval date is not the revision date.
Hash meaning
SHA-256 identifies this local summary, not original SPL XML or a label PDF.
Local summary SHA-256
e122383918fb3ec4d89194a62093dca3e9232c82ad760663ae50bf0b0b220e4f
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

GlobalRPh RX List - Ubrelvy

Open original reference

Open / share this exact local source

GlobalRPh-hosted RX List · Adults; oral UBRELVY; acute migraine. Selected renal and interaction constraints.

Renal method: CLcr in mL/min; renal table
Source date: February 2025
Retrieved: 2026-09-07

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

For adult acute migraine, the renal table uses 50 mg initially and, if needed, another 50 mg at least two hours later when CLcr is 15-29 mL/min. Avoid use when CLcr is below 15 mL/min. Interaction-specific restrictions still apply: with a moderate CYP3A4 inhibitor, the source permits 50 mg initially but no second dose within 24 hours; strong CYP3A4 inhibitors are contraindicated. This is acute treatment, not migraine prevention. Do not transplant preventive-drug schedules or assume a dialysis regimen from the severe-impairment row.

RDM36-rxlist-ubrogepant-ubrelvy-8284264216-C1 · Source locator: Dosage: dose modification table; contraindications; limitations of use.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/ubrelvy-drug/
Retrieved
2026-09-07
Renal-function method
CLcr in mL/min; renal table
Source date/version
February 2025
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
b27ebcf24bd0f938fee2323765ba9e85385ce8b1e3c900b696827af074872bb5

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 1 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fd9f9458-fd96-4688-be3f-f77b3d1af6ab
Source retrieval
2026-09-05. This is not the source publication or label revision date.
Original source type
multisource addition
Local text SHA-256
012839f7a1c0c6b224564e1fd28e6496cd8c26220b1c36a888685cb82d440bc4
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report